Glymphatic transport and ocular diseases.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical hypotheses with no original clinical trial data
PubMed 41448386 · doi:10.1016/j.preteyeres.2025.101433
What was done
This narrative review synthesized preclinical animal data and clinically grounded hypotheses regarding ocular glymphatic transport. It evaluated mechanisms of bidirectional fluid exchange and metabolic waste removal along the optic nerve (anterograde from retina and retrograde from brain) and cataloged pathways linking glymphatic disruption to specific ocular and neuro-ophthalmic pathologies.
What was found
The abstract provides no quantitative metrics, effect sizes, or pooled numbers. Mechanistically, the review identifies key contributors to ocular glymphatic impairment, including compromised laminar barrier integrity, pathological perivascular space enlargement, aquaporin-4 dysregulation, immature vasculature, and neuroimmune activation. It details glymphatic dysfunction across murine models and clinical conditions including glaucoma, diabetic retinopathy, ocular Alzheimer's disease manifestations, papilledema, spaceflight associated neuro-ocular syndrome, Terson syndrome, myopic optic neuropathy, age-related macular degeneration, neuromyelitis optica spectrum disorders, and retinal vasculitis.
Why it matters
It organizes emerging evidence on ocular fluid clearance into a unified mechanistic framework, outlining how impaired ocular waste removal may drive or exacerbate major blinding and neurodegenerative eye conditions.
Limits
As a narrative review, it lacks a systematic search methodology, risk-of-bias evaluation, and meta-analytic pooling. Many highlighted pathways depend heavily on rodent models, with direct in vivo validation of human ocular glymphatic kinetics remaining largely theoretical or preliminary.
Cited by
- supports The retina in the posterior chamber of the eye shares the same glymphatic clearance pathway as the brain.